Nektar Therapeutics (NKTR) Stock: Price, Forecast & Analyst Target
Nektar Therapeutics (NKTR) — MoonshotScore 11/100 (Weak band), calculated Nov 18, 2026. Price $30.20 (-7.19%), as of the Nov 20, 2026 trading session; market cap $1.03B.
Educational signal · not a buy or sell recommendation · How to read this
Nektar Therapeutics · NKTR · NASDAQ
Nektar Therapeutics is a biopharmaceutical company focused on discovering and developing innovative medicines for unmet medical needs. Their pipeline includes clinical-stage programs targeting cancer, autoimmune disorders, and other therapeutic areas.
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · Nektar Therapeutics (NKTR)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Bottom-tier quality, stalling growth and a full valuation, though the balance sheet is only middling. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Thin; Financial Safety: Okay; Valuation: Full; Growth Durability: Shrinking; Momentum: Slipping.
- quarterly revenue $9M (Q3 FY2026, quarter ended Sep 30, 2026)
- EPS beat 6 of the last 8 reports
- Altman Z -1.70 · Piotroski F 2
Holding back: weak fundamentals, soft growth, weak price trend
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 11 | Weak | |
| 11 | Weak | |
| 11 | Weak | |
| 11 | Weak | |
| 11 | Weak | |
| 11 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $30.20 | |
| Change on the day | -7.19% | |
| 52-week range | $30.20 – $109.00 | |
| Market capitalisation | $1.03B | — |
| Shares traded on the day | 1.02M |
Price & events
Other perspectives
Council score for Nektar Therapeutics (NKTR): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 8, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is Nektar Therapeutics (NKTR), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Nektar Therapeutics (NKTR) is listed on NASDAQ. It employs 63 people and is led by Howard W. Robin. In Q3 FY2026 it reported revenue of $9M and net income of -$56M. The market values it at $1.03B.
What do the latest results show for Nektar Therapeutics (NKTR)?
Short answer · as of
The most recent reported quarter, Q3 FY2026, carried revenue of $9M. Against analyst estimates the company has EPS beat 6 of the last 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2026 | $9M | -$56M | -$1.63 (diluted) |
| Q2 FY2026 | $10M | -$41M | -$1.23 (diluted) |
| Q1 FY2026 | $11M | -$45M | -$1.82 (diluted) |
| Q4 FY2025 | $22M | -$36M | -$1.78 (diluted) |
What are the financial strengths and risks for Nektar Therapeutics (NKTR)?
Short answer · as of
What is holding it back is weak fundamentals, soft growth, weak price trend. The distress and quality screens read Altman Z -1.70 · Piotroski F 2. Trailing ratios: ROE -29.3% · ROA -17.1% · current ratio 9.00 · earnings yield -13.9% · free-cash-flow yield -24.1%.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -1.70 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-29.3%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
What should you watch next at Nektar Therapeutics (NKTR)?
Short answer · as of
Current published price targets run low $50.00 · high $153.00 · consensus $107.20 · median $130.00 against a quoted price of $30.20 (as of Nov 20, 2026).
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
- No insider Form 4 transaction falls inside the window this page reads.
Checked against the records this page reads, on the dates shown above.
How does Nektar Therapeutics compare with its peers?
Short answer
Nektar Therapeutics's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $60.85 Nov 20, 2026 | $1.76B | 98 5-pillar Nov 18, 2026 | |
| $12.85 Nov 20, 2026 | $1.40B | 97 5-pillar Nov 18, 2026 | |
| $18.41 Nov 20, 2026 | $1.31B | 96 5-pillar Nov 18, 2026 | |
| $40.09 Nov 20, 2026 | $755M | 88 5-pillar Nov 18, 2026 | |
| $58.80 Nov 20, 2026 | $120B | 85 5-pillar Nov 18, 2026 | |
| $174.35 Nov 20, 2026 | $270B | 85 5-pillar Nov 18, 2026 | |
| $46.63 Nov 20, 2026 | $1.39B | 76 5-pillar Nov 18, 2026 | |
| $133.72 Nov 20, 2026 | $330B | 69 5-pillar Nov 18, 2026 | |
| $38.85 Nov 20, 2026 | $1.26B | 69 5-pillar Nov 18, 2026 | |
| $11.54 Nov 20, 2026 | $817M | 69 5-pillar Nov 18, 2026 | |
| $19.19 Nov 20, 2026 | $1.18B | 66 5-pillar Nov 18, 2026 | |
| $30.43 Nov 20, 2026 | $1.02B | 64 5-pillar Nov 18, 2026 | |
| Nektar Therapeutics (NKTR) — this page | $30.20 | $1.03B | 11 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $50.00 – $153.00
- Consensus target
- $107.20
- Median target
- $130.00
Consensus record · Captured .
Measured against a quoted price of $30.20 (as of Nov 20, 2026).
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held NKTR in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported NKTR in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Nektar Therapeutics (NKTR)?
What Investors Ask About Nektar Therapeutics (NKTR)
These answers are editorial: 1 of these 9 answers is drawn from the NKTR research dossier (written May 9, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for NKTR?
NKTR carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Nektar Therapeutics is a biopharmaceutical company focused on discovering and developing innovative medicines for unmet medical needs.
Is NKTR a good stock to buy?
Stock Expert AI does not rate NKTR buy, sell or hold. Nektar Therapeutics carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the NKTR stock price today?
The last price recorded for Nektar Therapeutics (NKTR), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the NKTR price target?
The analyst consensus price target for Nektar Therapeutics (NKTR), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What are the main risks for NKTR?
Nektar Therapeutics faces several key risks inherent to the biotechnology industry. Clinical trial failures represent a significant risk, as the success of its drug candidates depends on positive clinical data and regulatory approvals. High R&D spending and negative profit margins create financial challenges.
What are the key factors to evaluate for NKTR?
Nektar Therapeutics (NKTR) holds a MoonshotScore in the low range. To weigh it, read the analyst view under Analyst targets & estimates on this page. No dividend is currently offered, which is common for growth-oriented biopharmaceutical companies reinvesting earnings into research and development. Not financial advice.
How frequently does NKTR data refresh on this page?
NKTR's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven NKTR's recent stock price performance?
Nektar Therapeutics (NKTR) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative pipeline of clinical-stage drug candidates. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider NKTR overvalued or undervalued right now?
Nektar Therapeutics (NKTR) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 9, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 19 figures on this page — 11 from Financial Modeling Prep (FMP), 7 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com